4/14
03:16 am
imrx
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears [Yahoo! Finance]
Medium
Report
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears [Yahoo! Finance]
4/11
01:00 am
imrx
Medium
Report
4/6
04:05 pm
imrx
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Medium
Report
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
3/17
05:14 pm
imrx
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival [Yahoo! Finance]
Low
Report
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival [Yahoo! Finance]
3/17
04:35 pm
imrx
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Low
Report
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
3/9
08:03 am
imrx
Immuneering (IMRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $11.00 price target on the stock.
Medium
Report
Immuneering (IMRX) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $11.00 price target on the stock.
3/7
02:59 am
imrx
Medium
Report
3/6
08:25 am
imrx
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
3/6
07:45 am
imrx
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Medium
Report
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
3/2
04:40 pm
imrx
Immuneering to Present at the Leerink Global Healthcare Conference [Yahoo! Finance]
Low
Report
Immuneering to Present at the Leerink Global Healthcare Conference [Yahoo! Finance]
3/2
04:05 pm
imrx
Immuneering to Present at the Leerink Global Healthcare Conference
Low
Report
Immuneering to Present at the Leerink Global Healthcare Conference
2/28
02:23 am
imrx
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 [Yahoo! Finance]
Low
Report
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 [Yahoo! Finance]
2/18
04:37 pm
imrx
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/18
04:05 pm
imrx
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference